Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotype

Viral Immunology

Volumn 26, Issue 2, 2013, Pages 167-170

  Tamminen, Kirsi ^a   Huhti, Leena ^a   Vesikari, Timo ^a   Blazevic, Vesna ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; NOROVIRUS; PHENOTYPE; SALIVA ANALYSIS; VIRUS IMMUNITY; VIRUS LIKE AGENT;

ANIMALS; CALICIVIRIDAE INFECTIONS; CROSS REACTIONS; FEMALE; GENOTYPE; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; NOROVIRUS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

MUS; NOROVIRUS;

EID: 84876159796     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0082     Document Type: Article

References (26)

1. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011;365:2178-2187.
2. Blazevic V, Lappalainen S, Nurminen K, Huhti L, and Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011;29:8126-8133.
3. Bok K, Abente EJ, Realpe-Qiuntero M, et al. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J Virol 2009;83:11890-11901.
4. Donaldson EF, Lindesmith LC, Lobue AD, and Baric RS. Viral shape-shifting: Norovirus evasion of the human immune system. Nat Rev Microbiol 2010;8:231-241.
5. Giammanco GM, Rotolo V, Medici MC, et al. Recombinant norovirus GII.g/GII.12 gastroenteritis in children. Infect Genet Evol 2012;12:169-174.
6. Green KY. Caliciviridae: The noroviruses, pp. 949-980.
7. B. N. Fields (ed.), Fields Virology, 5. ed. vol. 1. 2007; Lippincott Williams & Wilkins, Philadelphia (Pa.).
8. Harrington PR, Lindesmith L, Yount B, Moe CL, and Baric RS. Binding of Norwalk virus-like particles to ABH histoblood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol 2002;76:12335-12343. (Pubitemid 35304332)
9. Huang P, Farkas T, Marionneau S, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: Identification of 4 distinct strain-specific patterns. J Infect Dis 2003;188:19-31. (Pubitemid 36829738)
10. Huhti L, Blazevic V, Nurminen K, Koho T, Hytonen VP, and Vesikari T. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol 2010;155:1855-1858.
11. Jiang X, Wang M, Graham DY, and Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992;66:6527-6532.
12. Jiang X, Wilton N, Zhong WM, et al. Diagnosis of human caliciviruses by use of enzyme immunoassays. J Infect Dis 2000; 181:S349-59. (Pubitemid 30395090)
13. Koho T, Huhti L, Blazevic V, et al. Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus. J Virol Methods 2012;179:1-7.
14. Lindesmith LC, Donaldson E, Leon J, et al. 2010. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol 2010;84:1800-1815.
15. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 2002;122:1967-1977. (Pubitemid 34651439)
16. Nurminen K, Blazevic V, Huhti L, et al. Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol 2011;83:525-531.
17. Puustinen L, Blazevic V, Salminen M, Hamalainen M, Rasanen S, and Vesikari T. Noroviruses as a major cause of acute gastroenteritis in children in Finland, 2009-2010. Scand. J Infect Dis 2011;43:804-808.
18. Reeck A, KaVanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010;202:1212-1218.
19. Rockx B, Baric RS, de Grijs I, Duizer E, and Koopmans MP. Characterization of the homo-and heterotypic immune responses after natural norovirus infection. J Med Virol 2005;77:439-446. (Pubitemid 41395875)
20. Siebenga JJ, Vennema H, Zheng DP, et al. Norovirus illness is a global problem: Emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis 2009;200:802-812.
21. Takanashi S, Wang Q, Chen N, et al. Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol 2011;49:3234-3244.
22. Tamminen K, Huhti L, Koho T, et al. A comparison of immunogenicity of norovirus GII-4 virus-like particles and Pparticles. Immunology 2012;135:89-99.
23. Thomas Francis J. On the doctrine of original antigenic sin. Proc Am Philosoph Soc 1960;104:572-578.
24. Tobin GJ, Trujillo JD, Bushnell RV, et al. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008;26:6189-6199.
25. Vega E, and Vinje J. Novel GII.12 norovirus strain, United States, 2009-2010. Emerg Infect Dis 2011;17:1516-1518.
26. Velasquez LS, Shira S, Berta AN, et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 2011;29:5221-5231.